Cherry Tree, while I agree with you in my primary account, and I don't have that many shares in the Roth's, I will consider selling at near the highs, and purchasing far more shares on retrenchment, if the price goes to what I consider an emotional high. $2, $3, even $5 wouldn't be an emotional high, depending on what's announced, but I believe $10 or more would be.
For those who can remember how an article in the NY Times on Judah Folkman sent stock in the company he worked for from $1 to over $100, that's what happens when emotion takes control and people want into a stock at any price. Once the dust settled and people realized that Dr. Folkman's advances were purely in mice, and while the Time's said that left alone he could cure cancer in two year, perhaps that would have been true in many different types of cancer and mice, but human trials would be decades. Sadly the technology didn't seem to work in people, but our technology would be a very different matter. GBM by itself would bring blockbuster results, all solid cancers would add at least a double digit multiplier, and probably triple digit or more. Give it time, it will be many years before DCVax-L can be approved in multiple solid cancers, but sales will grow in off label use before full approval is achieved.
Frankly if emotion goes crazy, something well in excess of $10, then I'll consider setting trailing stop losses in the primary account with the complete intent to buy back far more than I sell, and pay the taxes on my gains. Emotions can only last so long, eventually the price will probably retrench 50% or more. The higher we go, the greater retrenchment will be. Barring a miracle that achieves approval by all the regulators simultaneously, I don't see more than $5 to $7 being sustainable, and probably not that high.
Gary
